Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA3 | P0DMS8 | 5/20 | 0.80 |
| ▸ | PDE2A | O00408 | 8/20 | 0.72 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.72 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.72 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.72 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.72 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.72 |
| ▸ | NT5E | P21589 | 8/20 | 0.61 |
| ▸ | CD99 | P14209 | 1/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21089007 | 1.00 | ADORA3 (0.80) | ADORA3PDE2AADORA2AADORA1ADRA1A | |
| SCHEMBL12746256 | 1.00 | ADORA3 (0.80) | ADORA3PDE2AADORA2AADORA1ADRA1A | |
| SCHEMBL4451394 | 0.89 | ADORA3 (1.00) | ADORA3PDE2AADORA2AADORA1ADRA1A | |
| SCHEMBL3877328 | 0.89 | ADORA3 (1.00) | ADORA3PDE2AADORA2AADORA1ADRA1A | |
| SCHEMBL19843960 | 0.89 | ADORA3 (1.00) | ADORA3PDE2AADORA2AADORA1ADRA1A | |
| SCHEMBL22508566 | 0.87 | PDE2A (0.74) | ADORA3PDE2AADORA2AADORA1ADRA1A | |
| SCHEMBL23474142 | 0.85 | PDE2A (0.69) | ADORA3PDE2AADORA2AADORA1ADRA1A | |
| SCHEMBL14123296 | 0.85 | PDE2A (0.82) | ADORA3PDE2AADORA2AADORA1ADRA1A | |
| SCHEMBL24220765 | 0.85 | PDE2A (0.69) | ADORA3PDE2AADORA2AADORA1ADRA1A | |
| SCHEMBL10024078 | 0.85 | PDE2A (0.82) | ADORA3PDE2AADORA2AADORA1ADRA1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3947408-B1 | SALT OF TRIPHOSPHATE PHOSPHORAMIDATES OF NUCLEOTIDES AS ANTICANCER COMPOUNDS | NuCana plc (GB) | 2023-06-07 | — | — | EP | disclosed |
| US-11560400-B2 | Salts of diphosphate phosphoramidate of nucleosides as anticancer compounds | NuCana plc (GB) | 2023-01-24 | — | — | US | disclosed |
| EP-4043471-A1 | SALTS OF DIPHOSPHATE PHOSPHORAMIDATE OF NUCLEOSIDES AS ANTICANCER COMPOUNDS | Nucana PLC (GB) | 2022-08-17 | — | — | EP | disclosed |
| EP-3720864-B1 | SALTS OF DIPHOSPHATE PHOSPHORAMIDATE OF NUCLEOSIDES AS ANTICANCER COMPOUNDS | NuCana plc (GB) | 2022-01-05 | — | — | EP | disclosed |
| US-20210171566-A1 | SALTS OF DIPHOSPHATE PHOSPHORAMIDATE OF NUCLEOSIDES AS ANTICANCER COMPOUNDS | NuCana plc (GB) | 2021-06-10 | — | — | US | disclosed |
| WO-2020201751-A1 | SALT OF TRIPHOSPHATE PHOSPHORAMIDATES OF NUCLEOTIDES AS ANTICANCER COMPOUNDS | NuCana plc (GB) | 2020-10-08 | — | — | WO | disclosed |
| WO-2019110991-A1 | SALTS OF DIPHOSPHATE PHOSPHORAMIDATE OF NUCLEOSIDES AS ANTICANCER COMPOUNDS | NuCana plc (GB) | 2019-06-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210171566-A1 | SALTS OF DIPHOSPHATE PHOSPHORAMIDATE OF NUCLEOSIDES AS ANTICANCER COMPOUNDS | NUDT1, NTPCR, TYMP | ADORA3 358/4885PDE2A 1730/4885ADORA2A 265/4885 |
| US-11560400-B2 | Salts of diphosphate phosphoramidate of nucleosides as anticancer compounds | NUDT1, NTPCR, TYMP | ADORA3 358/4885PDE2A 1730/4885ADORA2A 265/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.